At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,608 enrolled
Drug / intervention
5-fluorouracil +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Clinical Trial Comparing Oral Uracil/Ftorafur (UFT) Plus Leucovorin (LV) With 5-Fluorouracil (5-FU) Plus LV in the Treatment of Patients With Stages II And III Carcinoma of the Colon
In Brief
A Phase 3 clinical trial evaluating 5-fluorouracil, leucovorin calcium, and 2 other interventions for Colorectal Cancer. Completed, enrolled 1,608 participants.
Detailed Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug is a way to kill more tumor cells. PURPOSE: Randomized phase III trial to determine the effectiveness of uracil, tegafur,and leucovorin compared with fluorouracil plus leucovorin in patients with resected stage II or stage III colon cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
Countries--
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 3CompletedFinished
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 1997
Primary CompletionMay 2006
First PostedSep 2006
Study CompletionApr 2009
TodayJul 2026
First PostedSep 21, 2006
Enrollment StartFeb 1, 1997
Primary CompletionMay 1, 2006
Study CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 9.3 yearsPosted 19.8 years ago
Interventions
5-fluorouracildrug
leucovorin calciumdrug
tegafurdrug
uracildrug